Securities Code: 002422 Securities Abbreviation: Kelun Pharmaceutical Announcement No.: 2026-039
Sichuan Kelun Pharmaceutical Co., Ltd.
Announcement on Adjusting the Upper Limit of Share Repurchase Price After the Implementation of 2025 Dividend Distribution
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or significant omissions.
Special Notes:
- Upper limit of share repurchase price before adjustment: not exceeding RMB 35 per share.
- Upper limit of share repurchase price after adjustment: not exceeding RMB 34.53 per share.
- Effective date of adjustment to the upper limit of share repurchase price: May 11, 2026 (ex-rights and ex-dividend date).
I. Basic Information on Share Repurchase
Sichuan Kelun Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the eleventh meeting of the eighth Board of Directors on January 4, 2026, and deliberated and approved the "Proposal on the Company's Share Repurchase Plan." The Company agreed to use its own funds to repurchase the Company's A-shares through centralized bidding transactions. The total amount of repurchase funds shall not be less than RMB 50,000,000 (inclusive) and not more than RMB 100,000,000 (inclusive). The repurchase price shall not exceed RMB 35 per share (inclusive). On January 6, 2026, the Company disclosed the "Resolution Announcement of the Eleventh Meeting of the Eighth Board of Directors" and the "Announcement on the Company's Share Repurchase Plan and Repurchase Report" on the designated information disclosure website Juchao Information Network (www.cninfo.com.cn), Securities Times, Shanghai Securities News, and China Securities Journal.